Corticosteroid-free immunosuppression in liver transplantation: An evidence-based review

George Sgourakis, Georgia Dedemadi

Abstract
Thirty-six randomized controlled trials and two meta-analyses were reviewed. With respect to adult patients undergoing first orthotopic liver transplantation (OLT), steroid replacement resulted in fewer cases of overall acute rejection in the corticosteroid-free immunosuppression arm. Initial steroid administration for two weeks and early tacrolimus monotherapy is a feasible immunosuppression regimen without steroid replacement, although further investigations are needed in view of chronic rejections. No significant differences were noted between the treatment groups in terms of patient and graft survival independently of steroid replacement. Renal insufficiency, de novo hypertension, neurological disorders and infectious complications did not differ significantly among steroid and steroid-free groups. Diabetes mellitus, cholesterol levels and cytomegalovirus infection are more frequent in patients within the steroid group. With respect to diabetes mellitus and hypercholesterolemia, the difference was independent of steroid replacement. In relation to transplanted hepatitis C virus patients, mycophenolate mofetil does not appear to have a significant antiviral effect despite early reports. Male gender of donors and recipients, living donors, cold ischemia times, acute rejection, and early histological recurrence were related to the development of advanced hepatitis. There is sufficient scientific clinical evidence advocating avoidance of the ab initio use of steroids in OLT.

Key words: Meta-analysis; Evidence based; Hepatitis C virus recurrence; Liver transplantation; Steroid withdrawal; Orthotopic liver transplantation

Core tip: Steroid replacement in orthotopic liver transplantation results in fewer cases of overall acute rejection in the corticosteroid-free immunosuppression arm. Tacrolimus monotherapy is a feasible immunosuppression regimen without steroid replacement, although further investigations are needed in view of chronic rejections. No significant differences were noted between the treatment groups in terms of patient and graft survival independently of steroid replacement. Male gender, living donors, cold ischemia times, acute rejection, and early histological recurrence are related to the development of advanced hepatitis. There is sufficient evidence advocating avoidance of the ab initio use of steroids in orthotopic liver transplantation.
plantation have had favorable outcomes, mainly due to the evolution of immunosuppressive agents. The use of steroids is still considered the mainstay of immunosuppression following liver transplantation as they decrease the risk of rejection. Nevertheless, they are also related to a large number of side-effects, as well as the potential recurrence of hepatitis C virus (HCV). The most common indication for liver transplantation is chronic HCV infection, accounting for about 40% of all transplants performed in the United States. Initially, the main concern after liver transplantation has always been the prevention of rejection, but current challenges also include preventing toxicity from anti-rejection (immunosuppressive) agents, while providing adequate immunosuppression to preserve optimal results. The advent of new agents addresses the need for immunosuppression to be more specific and free of the long-term side-effects of steroids. Immunosuppressive protocols currently focus on the avoidance of steroids and the use of a combination of different agents that reduce their respective toxicities. Many authors believe that early withdrawal of steroids can be made safer, but the duration of steroid administration after liver transplantation and the initiation of steroid-free immunosuppression remain controversial.

A number of randomized control trials (RCTs) have been published concerning outcomes of steroid avoidance in liver transplantation. Two recently published meta-analyses (including RCTs published up to 2007) failed to draw robust conclusions owing to the heterogeneity of studies.

The different immunosuppressive regimens, varying follow-up periods, small sample sizes, and high percentages of failure of participants to undergo the allocated treatment were important bias factors in these meta-analyses.

Various sufficiently powered RCTs have been published in the last six years, addressing specific issues of steroid avoidance in liver transplantation.

The purpose of this review was to better define the role of the steroid-free immunosuppressive regimens in liver transplant recipients according to Evidence-based Medicine Levels of Evidence.

RESEARCH

With the intention of identifying suitable studies, the electronic databases Medline, Embase, Pubmed and the Cochrane Library were used to search for articles from 1990 to 2013 in the English language literature which integrated the subsequent terms and/or combinations in their titles, abstracts or keyword lists: Randomized controlled trials, double-blind, liver transplantation, steroids, withdrawal, glucocorticoids, prednisone, methylprednisone, orthotopic liver transplantation and allograft. Where it was appropriate the above-mentioned terms were used in “(MESH)” (Pubmed and the Cochrane Library) otherwise the terms were combined with “AND/OR” and asterisks. Furthermore, the abstracts from national and international conferences were searched using online search engines corresponding to the particular conference.

After the initial screen additional criteria were imposed: (1) no less than one treatment group had early withdrawal or no steroid administration and a second treatment arm in which the patients received at least 3 mo of steroids; (2) study analysis was by intention to treat; and (3) studies of pediatric patients or both pediatric and adult population were excluded.

The two authors separately chose studies for inclusion and exclusion and reached consensus when they did not agree in the initial allocation. The subsequent variables were recorded: authors, journal and year of publication, country of origin, trial duration, participant demographics and data concerning rejection, adverse events, complications, follow up and survival.

CORTICOSTEROID-FREE IMMUNOSUPPRESSION IN LIVER TRANSPLANTATION

Thirty six RCTs (some of which were updated versions of already published studies) and two meta-analyses (including 19 and 21 of the above-mentioned RCTs, respectively) were reviewed. The evidence-based medicine levels of evidence and grades of Recommendation are shown in Tables 1 and 2. The baseline characteristics of the RCTs are summarized in Table 3. The strength and quality of the evidence is summarized in Table 4.

Adult patients undergoing first OLT for any indication

Rejection: Steroid replacement is presented with fewer cases of overall acute rejection in the corticosteroid-free immunosuppression arm (level of evidence: 1a-, degree of recommendation: D).

In the meta-analysis of Sgourakis et al, the corticosteroid-free immunosuppression group was equivalent to the steroid group in comparisons related to the following outcomes: acute rejection [mild: RR = 0.94 (0.69-1.29), P = 0.7] [moderate: RR = 1.02 (0.83-1.27), P = 0.8] [chronic rejection: RR = 1.52 (0.71-3.23), P = 0.2] and [steroid-resistant rejection: RR = 1.34 (0.87-2.08), P = 0.5]. Heterogeneity among studies in terms of acute rejection was observed. Considering overall acute rejection, in contrast to the results of meta-analysis (comparable results between treatment arms), metaregression showed that taking into account independently the RCT that replaced steroids [different regimens among studies e.g., daclizumab (DAC), rabbit antithymocyte globulin, mycophenolate mofetil (MMF), or daclizumab and MMF], the outcome favored the corticosteroid-free immunosuppression arm [RR = 1.31 (1.09-1.58), P < 0.01]], while the reverse applied when steroids were not replaced. In the meta-analysis by Segev et al, the rates of rejection within the first three months were somewhat higher among the steroid-free arms [RR = 1.31 (1.04-1.64), P = 0.02] in studies where steroids were stopped, but not replaced. In contrast, the
rates of rejection were markedly lower in the steroid-free arms \( [RR = 0.67 (0.48-0.96), \ P = 0.03] \) where steroids were replaced by other immunosuppressive agents. The rates of severe rejection also had a slightly higher trend, although not statistically significant, in studies where steroids were stopped, but not replaced \( [RR = 1.36 (0.63-2.93), \ P = 0.4] \). In studies in which steroids were replaced by another IS agent, severe rejection \( [RR = 0.37 (0.20-0.68), \ P = 0.001] \) was markedly lower in the steroid-free arms.

The above-mentioned meta-analyses failed to provide a conclusive answer as many single studies resulted in a troublesome heterogeneity. Such evidence is inconclusive, and can thus only generate Grade D recommendations.

Four RCTs were published after these two meta-analyses\(^{3,5,20,32,46}\).

Steroid replacement by daclizumab + MMF resulted in fewer cases of biopsy proven acute rejection (BPAR) at 24 wk in the corticosteroid-free immunosuppression arm (level of evidence: 1b, degree of recommendation: A).

The study by Otero \( et \ al\)\(^{39} \) [Tacrolimus (TACRO) + ST (3 mo) \( vs \) TACRO + Daclizumab + MMF - steroids replaced] enrolled 77 patients per treatment group which was required to provide 80% power to detect a difference between the null hypothesis (a rejection rate of 40% in both groups) and the alternative hypothesis (a rejection rate of 16% in the modified therapy group) with a 2-sided significance level of 0.05 to allow for an estimated 20% discontinuation rate. Significantly more patients in the standard therapy group experienced BPAR at 24 wk in comparison with patients in the modified (steroids replaced) therapy group \( (26.6\% \ vs \ 11.5\%, \ P = 0.017) \).

Initial steroid administration for two weeks and early Tacrolimus monotherapy is a feasible immunosuppression regimen without steroid replacement, although in view of chronic rejections, further investigations are needed (level of evidence: 1b, degree of recommendation: A).

In the study by Weiler \( et \ al\)\(^{40} \) [TACRO + ST (steroids) for the first 2 wk followed by TACRO \( vs \) TACRO + ST (6 mo) - steroids not replaced], acute rejection after initiation of the study medication was comparable for both groups. Steroid-free immunosuppressive therapy leads to a higher rate of chronic rejection \( (P = 0.023) \). This study was statistically powered (the initial scheduled sample size of 50 per treatment group was based on an estimated difference in the incidence of steroid side-effects of 15% between the primary study endpoints).

Ab initio tacrolimus monotherapy is a viable immunosuppressive approach in liver transplantation and is associated with lower rejection rates compared to microemulsified cyclosporine (CyA) (level of evidence: 2b, degree of recommendation: B).

Monotherapy (microemulsified CyA/TACRO) in both groups was used in the study by Cholongitas \( et \ al\)\(^{41} \). Patients in the TACRO group, as compared to those in the CyA group, had a significantly lower number of mild \( (P = 0.004) \), severe \( (P = 0.006) \) and total \( (P = 0.001) \) rejection episodes per patient. Chronic rejection was observed in 11% patients receiving CyA. No patient receiving TACRO experienced chronic rejection \( (P < 0.001) \). This study was not statistically powered.

**Adverse events:** Renal insufficiency, de novo hypertension, neurological disorders and infectious complications do not differ significantly among steroid and steroid-free groups (level of evidence: 1a, degree of recommendation: B).

In a meta-analysis by Sgourakis \( et \ al\)\(^{42} \), the corticosteroid-free immunosuppression group was equivalent to the steroid group in comparisons concerning the following outcomes: renal insufficiency \( [RR = 0.93 (0.78-1.11), \ P = 0.4] \) and severe renal insufficiency \( [odds ratio (OR) = 0.98 (0.52-1.81), \ P = 0.9] \) requiring hemofiltration, de novo

---

**Table 1  Evidence-based medicine levels of evidence\(^{41}\)**

| Level | Therapy/prevention, etiology/harm | Prognosis |
|-------|----------------------------------|-----------|
| 1a    | SR (with homogeneity\(^3\)) of RCTs | SR (with homogeneity\(^4\)) of inception cohort studies; CDR\(^2\) validated in different populations |
| 1b    | Individual RCT (with narrow Confidence Interval\(^1\)) | Individual inception cohort study with > 80% follow-up; CDR\(^2\) validated in a single population |
| 1c    | All or none\(^3\) | All or none case-series |
| 2a    | Individual inception cohort study | SR (with homogeneity\(^3\)) of either retrospective cohort studies or untreated control groups in RCTs |
| 2b    | Retrospective cohort study or follow-up of untreated control patients in an RCT; Derivation of CDR\(^2\) or validated on split-sample only |
| 2c    | “Outcomes” Research; Ecological studies | “Outcomes” research |
| 3a    | SR (with homogeneity\(^3\)) of case-control studies | SR (with homogeneity\(^3\)) of either retrospective cohort studies or untreated control groups in RCTs |
| 3b    | Individual case-control study | SR (with homogeneity\(^3\)) of case-control studies |

\(^1\) A systematic review (SR) that is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual studies. Studies displaying worrisome heterogeneity should be tagged with a “-” at the end of their designated level; \(^2\) Clinical decision rule (CDR) (These are algorithms or scoring systems that lead to a prognostic estimation or a diagnostic category); \(^3\) Met when all patients died before the Rx became available, but now none die on it; \(^4\) Split-sample validation is achieved when all patients died before the Rx became available, but now none die on it; \(^5\) Splitt-sample validation is achieved by collecting all the information in a single tranche, and subsequently artificially dividing this into “derivation” and “validation” samples. RCTs: Randomized control trials.

**Table 2  Grades of recommendation\(^{41}\)**

| Grade | Description |
|-------|-------------|
| A     | Consistent 1 studies |
| B     | Consistent 2 or 3 studies or extrapolations from level 1 studies |
| C     | Level 4 studies or extrapolations from level 2 or 3 studies |
| D     | Level 5 evidence or troubling inconsistent or inconclusive studies of any level |
| Ref. | Indication | Recipients | Regimens | Outcomes | Study duration | Rejection treatments protocols |
|------|------------|------------|----------|----------|----------------|--------------------------------|
| Belli et al[6] 2001 | HCV positive | Group A = 13, Group B = 11, Group C = 13 | RATG + AZA + CyA + ST (3 mo) / RATG + AZA + CyA | Acute rejection, chronic rejection, HCV recurrence | November 1997-November 1999 | NS |
| Boillot et al[7] 2005 | Adult patients undergoing first OLT | Group A = 351, Group B = 347, Group C = 31 | TACRO + daclizumab/TACRO + ST (3 mo) | Acute rejection, corticosteroid resistant acute rejection, graft survival | July 2000-February 2002 | Increasing TACRO dose and/or steroids |
| Eason et al[10] 2003 | Adult patients undergoing first OLT | Group A = 59, Group B = 60 | RATG + TACRO + MMF/ST (3 mo) + TACRO + MMF | Patient survival, graft survival, rejection, adverse events, HCV recurrence | December 1999-August 2002 | Increasing TACRO or adding MMF or sirolimus; steroids if no improvement after 48 h |
| Filipponi et al[11] 2004 | HCV positive | Group A = 74, Group B = 66, Group C = 31 | Basiliximab + ST (3 mo) + CyA + AZA / basiliximab + CyA | HCV recurrence, patient survival, graft survival, treatment failure | October 1998-March 2001 | Methylprednisolone bolus for 3 d |
| Kato et al[14] 2007 | HCV positive | Group A = 15, Group B = 16 | 1st Period TACRO + daclizumab/TACRO + ST (3 mo)/2nd Period TACRO + daclizumab + MMF/TACRO + ST (3 mo) + MMF | Fibrosis stage, acute rejection, adverse events, predictors | November 1999-November 2002 | Methylprednisolone bolus ± taper; OKT3 for severe or treatment-resistant rejection |
| Klintmalm et al[16] 2007 (updated by Klintmalm 2011) | HCV positive | Group A = 80, Group B = 79, Group C = 133 | TACRO + ST (3 mo)/TACRO + ST (3 mo) + MMF/daciluzumab + TACRO + MMF | Risk factors, rejection, HCV recurrence, treatment failure | NS | Methylprednisolone bolus ± taper; mild rejection increasing tacrolimus ± antimitabolite (MMF or azathioprine) Antilymphocyte antibody for corticosteroid-resistant rejection |
| Langrehr et al[18] 2002 | HCV positive | Group A = 27, Group B = 26 | TACRO + ST (3 mo)/TACRO + MMF | Rejection, HCV recurrence | NS | NS |
| Lerut et al[19] 2004 (updated by Lerut 2008) | Adult patients undergoing first OLT | Group A = 50, Group B = 50 | TACRO + ST (3 mo)/TACRO | Acute rejection, graft survival, adverse events | NS | NS |
| Llado et al[20] 2006 (updated by Llado 2008) | Adult patients undergoing first OLT | Group A = 102, Group B = 96 | Basiliximab + CyA + ST (3 mo)/basiliximab + CyA | Acute rejection, patient survival, graft survival, infection | April 2001-September 2004 | Methylprednisolone bolus for 3 d ± taper ± increase in TACRO |
| Lupor et al[21] 2005 (updated by Lupor 2008) | Adult patients undergoing first OLT | Group A = 20, Group B = 21 | CyA + ST (3 mo)/CyA + Basiliximab | Acute rejection | NS | Methylprednisolone bolus for 3 d |
| Margarit et al[22] 2005 | Adult patients undergoing first OLT | Group A = 28, Group B = 32 | TACRO/TACRO + ST (3 mo) | Acute rejection, severe acute rejection, HCV recurrence, 3 yr-graft survival | October 1998-September 2000 | Increasing tacrolimus dose; methylprednisolone bolus for 3 d ± taper for severe rejection |
| Moench et al[23] 2007 (updated by Weiker 2010) | Adult patients undergoing first OLT | Group A = 56, Group B = 54 | TACRO/TACRO + ST (6 mo) | Patient survival, graft survival, acute rejection, chronic rejection, adverse events | February 2000-August 2004 | Methylprednisolone; tacrolimus adjusted higher level |
| Study | Year | Group A | Group B | Treatment | Outcome |
|-------|------|---------|---------|-----------|---------|
| Nashan et al. | 2001 | 27 | 54 | TACRO + ST (3 mo) | Graft and patient survival, incidences of TAC monotherapy, acute rejection, survival, re-transplantation, adverse events |
| Pelkor et al. | 2005 | 20 | 36 | TACRO + daclizumab + MMF | Up to 3 full courses of high dose steroids |
| Regnier et al. | 2003 | 35 | 54 | TACRO + ST (3 mo) | NS |
| Sgourakis et al. | 2005 | 15 | 15 | Basiliximab + CyA + ST (6 mo)/CyA + AZA | NS |
| Takada et al. | 2006 | 22 | 15 | TACRO + MMF + ST (3 mo)/TACRO + MMF | NS |
| Tisone et al. | 2007 | 20 | 29 | TACRO + MMF + ST (3 mo)/TACRO + MMF + dacarbazine | NS |
| Studenik et al. | 2008 | 78 | 78 | Basilimab + CyA + ST (6 mo)/CyA + MMF | NS |
| Neumann et al. | 2009 | 68 | 67 | Basilimab + CyA + ST (6 mo)/CyA + MMF | NS |
| Neumann et al. | 2010 | 84 | 87 | Basilimab + CyA + ST (6 mo)/CyA + MMF | Event-free survival: histological recurrence of hepatitis C, BPAR resistant to 2 sets of steroid pulse therapy, patient survival, acute rejection, chronic rejection, steroid-resistant rejection, death of recipient, death of patient |
| Neumann et al. | 2011 | 35 | 36 | Basilimab + CyA + ST (6 mo)/CyA + MMF | NS |
| Neumann et al. | 2012 | 79 | 78 | Basilimab + CyA + ST (6 mo)/CyA + MMF | Event-free survival: histological recurrence of hepatitis C, BPAR resistant to 2 sets of steroid pulse therapy, patient survival, acute rejection, chronic rejection, steroid-resistant rejection, death of recipient, death of patient |
| Lerut et al. | 2013 | 78 | 78 | Basilimab + CyA + ST (6 mo)/CyA + MMF | NS |
| Lerut et al. | 2014 | 15 | 15 | Basilimab + CyA + ST (6 mo)/CyA + MMF | NS |
| Lerut et al. | 2015 | 78 | 78 | Basilimab + CyA + ST (6 mo)/CyA + MMF | NS |
| Study | Patient Group | Immunosuppression | Outcomes | Study Period | Rejection Management |
|-------|---------------|-------------------|----------|--------------|---------------------|
| Becker et al. 2008 | Adult patients undergoing first OLT or split liver allograft transplantation | Group A = 305 TACRO + daclizumab/TACRO + MMF | Rejection, overall survival and allograft survival, renal function | March 2005-June 2007 | Acute rejection was treated with three 1 g/d methylprednisolone |
| Cholongitas et al. 2008 | Adult patients undergoing first OLT | Group A = 36 CyA/TACRO | Death | January 1996-January 1997 | Steroid pulse therapy, ACAR was treated with an increase in TACRO to 15 ng/mL without a corticosteroid bolus and recycle. Moderate to severe ACR 4) was treated with a 1.0-g bolus of methylprednisolone, followed by a 6-d steroid taper of intravenous methylprednisolone or oral prednisone |
| Gerhardt et al. 2009 | Adult patients undergoing first OLT | Group A = 8 CNI/MMF vs a MMF/prednisone | Renal function | May 2003-May 2005 | “mild” rejection episodes were treated with steroid boluses |
| Klintmalm et al. 2011 | Chronic liver disease | Group A = 77 TACRO + ST (β mo) TACRO + ST (3 mo) + MMF/daclizumab + TACRO + MMF | Acute rejection, HCV recurrence, survival | NS |
| Lladó et al. 2008 | HCV positive | Group A = 46 Basiliximab + CyA + ST (β mo)/basiliximab + CyA | Acute rejection, patient and graft survival, adverse events (infections and metabolic decompensations), HCV recurrence | April 2001-September 2004 | Methylprednisolone bolus for 3 d ± taper ± increase in TACRO |
| Lupo et al. 2008 | Adult patients undergoing first OLT | Group A = 21 CyA + ST (β mo)/CyA + Basiliximab | Acute rejection, patient and graft survival, HCV recurrence, medical and surgical complications, infections | November 2002-November 2005 | Methylprednisolone bolus for 3 d |
| Otomo et al. 2009 | Adult patients undergoing first OLT | Group A = 79 TACRO + ST (3 mo)/TACRO + Daclizumab + MMF | Acute rejection, time to rejection, patient and graft survival, HCV status, hepatic and renal function | May 2002-December 2003 | Up to 2 courses of high dose steroids for 3 d Corticosteroid-resistant rejection episode was treated with anti-lymphocyte therapy |
| Weiler et al. 2010 | Adult patients undergoing first OLT | Group A = 56 TACRO/TACRO + ST (6 mo) All patients TACRO + steroids for the first 2 wk TACRO/TACRO + ST (6 mo) | Patient survival, organ survival, steroid side-effects, acute rejection, chronic rejection, HCV recurrence | February 2000-August 2004 | Methylprednisolone; tacrolimus adjusted higher level |
| Junge et al. 2005 | Recipients with autoimmune hepatitis | Group A = 14 TACRO + steroids/TACRO + MMF | Graft and patient survival, acute rejection, liver functions, glucose metabolism, bone density, blood pressure, renal function, drug-related side-effects, infections | NS | Mild or moderate rejection: methylprednisolone pulse therapy, severe rejection: high-dose steroids + monoclonal antibody |
| Bonaccorsi-Riani et al. 2012 | HCV positive | Group A = 14 TACRO + steroids (2 mo)/TACRO + placebo | 1 and 5 yr survival; HCV recurrence, retransplantation, death | NS | NS |

Numbers within brackets in the third column show the number of hepatitis C virus (HCV) transplanted patients; CyA: Cyclosporine; TACRO: Tacrolimus; ST: Steroids; RATG: Rabbit antithymocyte globulin; AZA: Azathioprine; MMF: Mycophenolate mofetil; OKT3: Murine monoclonal IgG2a antibody; EC-MPS: Enteric-coated mycophenolate sodium; BPARI: Biopsy-proven acute rejection; S4: Stage 4; CRC: Corticosteroid-resistant rejection; OLT: Orthotopic liver transplantation; BPAR: Biopsy proven acute rejection; NS: Non-significance.
The development of post-transplant diabetes mellitus [RR = 1.86 (1.43-2.41), P < 0.001], cholesterol levels at 6 mo [weighted mean difference (WMD) = 19.71 (13.7-25.7), P < 0.001] and CMV infection [RR = 1.47 (0.99-2.17), P < 0.05] favored the corticosteroid-free immunosuppression group as reported by Sgourakis et al. [42].

Similar results were published in the meta-analysis by Segev et al. [41]: Significant reductions in cholesterol [standard mean difference = -0.41 [-0.62]-0.20, P < 0.001] and the risk of CMV infection [RR = 0.52 (0.35-0.76), P = 0.001], were observed in the steroid-free groups.

Both meta-analyses had statistically significant heterogeneity of studies, especially in CMV infection and some studies had wide Confidence Intervals.

Metaregression analysis in the former disclosed that there was no difference between studies that replaced or did not replace steroids in the corticosteroid-free immunosuppression group (P = 0.087). The latter also supports that the risk of diabetes [RR = 0.29 (0.18-0.47), P < 0.001], was markedly lower in the steroid-free arms.

Four RCTs were published after these two meta-

---

### Table 4 Summary of the strength and quality of the evidence

| Intervention | Level of evidence | Degree of recommendation |
|--------------|-------------------|--------------------------|
| Studies including adult patients undergoing first OLT for any indication | 1a- | D |
| Steroid replacement results in fewer cases of overall acute rejection in the corticosteroid-free immunosuppression arm | 1b | A |
| Steroid replacement by daclizumab + MMF results in fewer cases of BPAR at 24 wk in the corticosteroid-free immunosuppression arm | 2b | B |
| Initial steroid administration for two weeks and early tacrolimus monotherapy is a feasible immunosuppression regimen without steroid replacement, although in view of chronic rejections, further investigations are needed. Ab inito tacrolimus monotherapy is a viable immunosuppressive approach in liver transplantation and is associated with lower rejection rates compared to microemulsified cyclosporine | 1b | A |
| Renal insufficiency, de novo hypertension, neurological disorders and infectious complications do not differ significantly among steroid and steroid-free groups | 1a- | D |
| Diabetes mellitus, cholesterol levels and CMV infection had a higher incidence in the steroid group. The differences in cases of diabetes mellitus and hypercholesterolemia are independent of steroid replacement | 1a- | D |
| Hypertension, thrombocytopenia, renal impairment and overall incidence of infections do not differ significantly among steroid and steroid-free groups (steroids replaced by daclizumab + MMF) | 1b | A |
| Early tapering down of steroids to tacrolimus monotherapy is possible with significantly fewer cases of diabetes and hypercholesterolemia | 1b | A |
| Side-effects related to monotherapy with microemulsified cyclosporine or tacrolimus are comparable | 2b | B |
| Complete corticosteroid avoidance in adult OLT using basiliximab induction with CNI and EC-MPS maintenance is as safe and as effective as standard corticosteroid containing immunosuppression | 2b | B |
| No significant differences were noted between treatment groups in terms of patient and graft survival regardless of steroid replacement | 1b | A |
| Actuarial 5-yr patient and graft survival related to monotherapy with microemulsified cyclosporine or tacrolimus are comparable | 2b | B |
| Steroid withdrawal should be attempted in OLT recipients with underlying autoimmune hepatitis | 2b | D |
| Which immunosuppression regimen? Both, tacrolimus-based regimens with daclizumab induction or the addition of MMF, allow for avoidance of steroid treatment | 1b | A |
| Studies addressing exclusively transplanted HCV patients | 1a- | D |
| A significant reduction in HCV recurrence independent of steroid replacement may be expected in steroid-free groups | 1b | A |
| MMF does not appear to have a significant antiviral effect despite early reports | 2b | B |
| Male gender of donors and recipients, living donors, cold ischemia times, acute rejection, and early histological recurrence are related to the development of advanced hepatitis | 1b | A |
| Donor age, grade 2 inflammation at day 90 or one-year liver biopsy and diagnosis of acute hepatitis may be associated with the development of bridging fibrosis or cirrhosis | 2b | B |

CMV: Cytomegalovirus; MMF: Mycophenolate Mofetil; OLT: Orthotopic liver transplantation; EC-MPS: Enteric-coated mycophenolate sodium; BPAR: Biopsy-proven acute rejection; CNI: Calcineurin inhibitor; HCV: Hepatitis C virus.

hypertension development [RR = 1.07 (0.9-1.27), P = 0.4], neurological disorders [OR = 0.76 (0.51-1.13), P = 0.2] and infectious complications [RR = 1.07 (0.96-1.2), P = 0.2].

In a meta-analysis by Segev et al [41], the corticosteroid free-immunosuppression group was equivalent to the steroid group in comparisons related to the following outcomes: cumulative risk of hypertension [RR = 0.84 (0.69-1.02), P = 0.08] and infection [RR = 0.97 (0.88-1.08), P = 0.6].

Degree of recommendation “B” was extrapolated because data used in the included studies were clinically different despite the fact that there was no heterogeneity or wide Confidence Intervals among outcomes in both meta-analyses.

Diabetes mellitus, cholesterol levels and cytomegalovirus (CMV) infection showed a higher incidence in the steroid group. The differences in cases of diabetes mellitus and hypercholesterolemia were independent of steroid replacement (level of evidence: 1a-, degree of recommendation: D).
analyses. Hypertension, thrombocytopenia, renal impairment and overall incidence of infections do not differ significantly among steroid and steroid-free groups (steroids replaced by daclizumab + MMF) (level of evidence: 1b, degree of recommendation: A).

In the sufficiently powered study by Otero et al., TACRO + ST (3 mo) vs TACRO + daclizumab + MMF - steroids replaced, although more patients in the standard therapy group reported hypertension (26.6% vs 20.5%), thrombocytopenia (15.2% vs 12.8%), new-onset diabetes mellitus (13.9% vs 9.0%), and renal impairment (27.8% vs 19.2%), these differences were not statistically significant. Overall infections occurred in 19.2% of the modified therapy group vs 11.4% of the standard therapy group (P = 0.172).

Early tapering down of steroids to a tacrolimus monotherapy is possible with significantly fewer cases of diabetes and hypercholesterolemia (level of evidence: 1b, degree of recommendation: A).

In the sufficiently powered study by Weiler et al., all patients TACRO + steroids for the first 2 wk followed by TACRO/TACRO + ST (6 mo) - steroids not replaced, statistically significant differences in diabetes (53% in the steroid group vs 30%, P = 0.024) and hypercholesterolemia (41% in the steroid group vs 10%, P = 0.002) were demonstrated at six months. A statistical difference in the osteoporosis rate was insignificant.

Side-effects related to monotherapy by microemulsified cyclosporine or tacrolimus are comparable (level of evidence: 2b, degree of recommendation: B).

Monotherapy (microemulsified CyA/TACRO) in both groups was used in the study by Cholangitas et al. Twenty-eight (77%) patients in the CyA group developed renal dysfunction (defined as GFR < 60 mL/min) at least once, compared to 45 (36%) in the TACRO group (P < 0.001), although this difference remained at the margin of significance at five years. Side-effects related to immunosuppression were similar between the two groups at one, two and five years after liver transplantation.

Complete corticosteroid avoidance in adult OLT using basiliximab induction with calcineurin inhibitor and enteric-coated mycophenolate sodium (EC-MPS) maintenance is as safe and as effective as standard corticosteroid containing immunosuppression (level of evidence: 2b, degree of recommendation: B).

In the study by Ramirez et al., Basiliximab + TACRO + EC-MPS + ST (6 mo) vs basiliximab + TACRO + EC-MPS, mean cholesterol levels were similar in both groups from baseline to 12 mo post-OLT. Mean arterial pressure levels were significantly higher in the corticosteroid group as opposed to the corticosteroid-free group at three and 12 mo post-OLT.

Graft and patient survival: No significant differences were noted between treatment groups in terms of patient and graft survival regardless of steroid replacement (level of evidence: 1b, degree of recommendation: A).

In the meta-analysis by Sgourakis et al., relevant comparisons were equivalent among the corticosteroid-free immunosuppression group vs the steroid group in terms of the following outcomes: overall number of deaths during follow-up [RR = 0.9 (0.72-1.13), P = 0.36], one-year patient survival [OR = 0.1 (0.69-1.45), P = 0.9], one-year graft survival [OR = 0.8 (0.56-1.15), P = 0.2], retransplantation [OR = 0.82 (0.45-1.52), P = 0.6], deaths up to 6 mo [RD = -0.01 (-0.04-0.02), P = 0.5] and 3-mo graft survival [OR = 1.24 (0.79-1.25), P = 0.4]. Only 7 studies gave detailed information on the percentage of patients in each treatment arm which had received the allocated regimen. The corticosteroid-free immunosuppression group was superior in terms of the number of patients receiving the allocated intervention [OR = 1.55 (1.17-2.05), P = 0.003].

No differences between steroid-free and steroid-based protocols were observed in terms of death [RR = 0.95 (0.73-1.24), P = 0.7] and graft loss [RR = 0.95 (0.76-1.19), P = 0.6] in the meta-analysis by Segev et al.

Both meta-analyses included some studies with wide Confidence Intervals, while data in the latter meta-analysis have not been extrapolated to the specific time period.

In the sufficiently powered study by Otero et al. (steroids replaced) no significant differences emerged between treatment groups in terms of patient and graft survival; however, the time to rejection for patients in the standard therapy group was significantly shorter than that noted in the modified therapy group (P = 0.044).

In the sufficiently powered study by Weiler et al. (steroids not replaced), patient (P = 0.236) and graft survival (P = 0.509) was similar in both groups. In total, eight patients (7.3%) were retransplanted within 5 years, four (7.1%) from the placebo group, and four (7.4%) from the steroid group.

In the study by Ramirez et al., no significant differences in patient and death-censored graft survival rates between the two groups (corticosteroids and corticosteroid-free) were observed. The 1-, 3-, and 5-year patient survival were as follows: 100% vs 95%, 85% vs 63%, and 80% vs 63%. The 1-, 3-, and 5-year graft survival rates in the corticosteroid and corticosteroid-free groups were as follows: 100% vs 95%, 85% vs 63%, and 75% vs 63%, respectively.

Actuarial 5-year patient and graft survival related to monotherapy with microemulsified cyclosporine or tacrolimus are comparable (level of evidence: 2b, degree of recommendation: B).

Monotherapy in both groups was used in the study by Cholangitas et al. Actuarial survival according to Kaplan-Meier curves at five years was 72% for TACRO and 70% for CyA. Graft survival at five years was 59% for TACRO and 57% CyA. Neither patient survival nor graft survival differed statistically between the groups. Only two patients in the TACRO group required a second LT, compared to five (14%) in the CyA group (P = 0.007).

Liver transplant recipients with autoimmune hepatitis: Steroid withdrawal should be attempted in OLT recipients with underlying autoimmune hepatitis (level of
evidence: 2b-, degree of recommendation: D).

Only one RCT[18] exclusively analyzed patients with autoimmune hepatitis (AIH). The 2-year survival in the prednisone group was 93% vs 100% in the steroid-free group who received MMF. No differences were observed with regard to graft function, acute rejection, renal function, and infectious complications. The prednisone group showed significantly elevated glucose levels with higher HbA1c and insulin requirements. The mean serum cholesterol level was significantly lower and bone density showed significant improvement in the MMF as opposed to the prednisone group (both outcomes: \( P < 0.01 \)). The authors suggested that steroid withdrawal should be attempted in OLT recipients with underlying AIH. This is a low sample size study, where the randomization procedure and patient allocation were not disclosed.

Which steroid-free regimen? Both, TACRO-based regimens with DAC induction or the addition of MMF, allow for avoidance of steroid treatment (level of evidence: 1b, degree of recommendation: A).

In the large sufficiently powered, multicentre, randomized, open-label, parallel group, phase III trial conducted by Becker et al[9], 602 patients were enrolled and randomized to treatment: 305 patients were randomized to the TACRO/DAC group and 297 to the TACRO/MMF group. Approximately 70% of patients in each group completed the study. The overall estimated rate of patients free of BPAR that required treatment within 3 mo of transplantation was 81.5% in the TACRO/DAC group and 82.2% in the TACRO/MMF group. Differences were found in the incidence of causally related adverse events which was significantly lower in the TACRO/DAC group than that in the TACRO/MMF group: 76.1% and 82.8%, respectively \( (P < 0.05) \). Conversely, renal disorders were more often reported as an adverse event in the TACRO/DAC group than in the TACRO/MMF group. The authors concluded that TAC monotherapy after DAC induction was associated with significantly less leucopenia and bacterial infection. Both TACRO-based regimens, DAC induction or dual therapy with MMF, allow for avoidance of steroid treatment, thereby eliminating risks associated with steroids, while providing satisfactory levels of immunosuppression.

Results of studies addressing exclusively transplanted HCV patients

HCV recurrence: A significant reduction in HCV recurrence independent of steroid replacement may be expected in the steroid-free groups (level of evidence: 1a-, degree of recommendation: D).

In the meta-analysis by Sgourakis et al[13], the corticosteroid-free immunosuppression group was equivalent to the steroid group in comparisons pertaining to the following outcomes: overall deaths in HCV patients \( (RR = 0.92 (0.52-1.65), P = 0.8) \), deaths in HCV-recurrence patients \( (RD = 0.01 (0.05)-0.07, P = 0.7) \), one-year patients \( (OR = 0.63 (0.37-1.08), P = 0.1) \) and one-year graft survival \( (OR = 0.68 (0.42-1.08), P = 0.08) \). The corticosteroid-free immunosuppression group was superior in terms of the relative risk of HCV recurrence \( (RR = 1.15 (1.01-1.13), P < 0.05) \), acute graft hepatitis \( (OR = 3.15 (1.18-8.40), P = 0.03) \) and the number of patients failing treatment: collectively, patients with graft loss/deaths/withdrawal \( (OR = 1.87 (1.33-2.63), P = 0.0001) \). Metaregression analysis also disclosed that there was no difference between studies that replaced or did not replace steroids in the corticosteroid-free immunosuppression group in terms of HCV recurrence \( (P = 0.610) \).

Significant reductions in HCV recurrence \( (RR = 0.90 (0.82-0.99), P = 0.03) \) were observed in the steroid-free groups in the meta-analysis by Segev et al[11].

The fact that both the above-mentioned meta-analyses included studies with less than 6 mo of follow-up and that HCV recurrence is defined in many different ways among studies (Ishak score, fibrosis, HCV RNA etc.) must be taken into consideration.

Eight RCTs exclusively addressed HCV transplanted patients after the publication of the two meta-analyses[9,13,24,29,32,36,40], three of which involved deceased donors[19,24,28], one a living donor[18] and the remaining four all etiologies of deceased donor transplantation[29,32,34].

In the sufficiently powered study by Neumann et al[29], patients who had received antiviral treatment during the study were excluded. The percentage of patients free of HCV recurrence at 12 mo was 19.1% for the TACRO/DAC steroid-free protocol and 13.8% for the TACRO/ST protocol, with a significant difference in survival curves between treatments \( (P = 0.020) \). HCV recurrence censored for antiviral treatment favored the TACRO/DAC immunosuppression protocol at a rate of 20.2% vs 13.1% in the TACRO/ST group \( (P = 0.022) \). The overall estimated rate of patient survival was significantly lower in the TACRO/DAC arm \( (P = 0.025) \). The estimated rate of graft survival was numerically lower in the TACRO/DAC arm. The rate of graft loss was 19.4% in the TACRO/DAC arm and 8.8% in the TACRO/ST arm. The overall frequency of BPAR was significantly lower in the TACRO/DAC than in the TACRO/ST arm \( (P = 0.048) \).

Although there was a tendency for later HCV recurrence and a lower incidence of rejection, the authors also observed a higher dropout rate and a lower patient survival rate with TACRO/DAC compared to the TACRO/ST arm and concluded that it is difficult to recommend a steroid-free protocol for HCV-positive patients due to the afore-mentioned study limitations.

In the study by Manousou et al[19], antiviral treatment for HCV recurrence [after Ishak stage 4 was reached] was used in six out of 54 monotherapy (MT) and eight out of 49 triple therapy (TT) patients, with three in each group achieving sustained virological response. Overall mortality was not significantly different between the groups. The difference in reaching the primary endpoint (Stage 4 fibrosis) was significantly \( (P = 0.045) \) in favor of triple therapy patients. Rejection episodes assessed by protocol biopsies that were histologically proven and/or required
methylprednisolone (30% vs 49%) were less frequent in the MT group. Retransplantation rates (7.8% for TT and 9.6% for MT) and chronic rejection rates (2% for TT and 3.8% for MT) were not different. This randomized trial supported the benefit of low-dose and slowly tapered steroids as well as azathioprine after liver transplantation for HCV-positive recipients.

MMF does not appear to have a significant antiviral effect despite early reports (level of evidence: 1b, degree of recommendation: A).

In the sufficiently powered study by Klintmalm et al[15], clinically significant HCV in the three arms [TACRO + ST (3 mo)/TACRO + ST (3 mo) + MMF/dacilizumab + TACRO + MMF] occurred in 69.5%, 75.9%, and 68.1% within 2 years. None of these differences was statistically significant. The 1- and 2-year patient and graft survival rates in the three arms were similar. The 2-year graft survival rates were 79.1%, 79.8%, and 85.1%, respectively (no significant differences). By day 730, clinically significant acute rejection had occurred in 14.3%, 12.5%, and 13.7% of the patients in the three arms. None of the differences among the groups was significant. The authors found no evidence that MMF influenced HCV progression.

With regard to living donor liver transplantation in the study by Takada et al[24], antiviral treatment with interferon and ribavirin was considered for HCV recurrence. A sustained virological response was achieved in 44.4% of patients in the ST group and in 66.7% of patients in the MMF group (P = 0.16). The 1-, 3-, and 5-year overall survival rates were 94.1%, 87.6%, and 82.7%, respectively, for the ST group and 92.5%, 84.5%, and 81.0%, respectively, for the MMF group (P = 0.28). BPAR requiring treatment with an ST bolus injection occurred in four patients from the ST group and in 13 patients from the MMF group (P = 0.051).

Predictors of the development of advanced hepatitis: Male gender of donors and recipients, living donors, cold ischemia times, acute rejection, and early histological recurrence are related to the development of advanced hepatitis (level of evidence: 1b, degree of recommendation: A).

In the sufficiently powered study by Klintmalm et al[15], Cox Regression showed that male gender of donors and recipients, living donors, cold ischemia times, acute rejection, and early histological recurrence (grade 2 inflammation on the 90-d liver biopsy sample or stage 1 fibrosis at one-year biopsy) were related to the development of advanced hepatitis.

Predictors of advanced fibrosis: Donor age, grade 2 inflammation at day 90 or one-year liver biopsy and diagnosis of acute hepatitis may be associated with the development of bridging fibrosis or cirrhosis (level of evidence: 2b, degree of recommendation: B).

According to a multivariate Cox analysis, the donor age and grade 2 inflammation at day 90 or one-year liver biopsy were associated with the development of bridging fibrosis or cirrhosis; the administration of murine monoclonal IgG2a antibody or thymoglobulin approached significance[19]. In yet another study, two independent predictors of fibrosis stage ≥ 4 were significant: randomization to monotherapy [OR = 0.7 (0.066-0.847)] and diagnosis of acute hepatitis [OR = 3.59 (1.108-9.823)][26]. However, the former study[15] observed subjects for only 2 years after transplantation, and some patients refused liver biopsy in the second year. Thus, the authors could not dismiss the possibility that differences might have been observed if all subjects had been biopsied or the follow-up had been longer. The latter study[26] was not sufficiently powered.

CONCLUSION

Considering adult patients undergoing first OLT

It seems that steroid replacement results in fewer cases of overall acute rejection in the corticosteroid-free immunosuppression arm, although the evidence is of moderate quality. Steroid replacement by daclizumab plus MMF or early tacrolimus monotherapy after initial steroid administration for two weeks, are strong alternatives. In terms of patient and graft survival and regardless of steroid replacement, steroid-free immunosuppression is strongly recommended.

Adverse events such as renal insufficiency, de novo hypertension, neurological disorders and infectious complications did not differ significantly among steroid and steroid-free groups. Diabetes mellitus, cholesterol levels and CMV infection showed a higher incidence in the steroid group. The differences in cases of diabetes mellitus and hypercholesterolemia were independent of steroid replacement.

Considering transplanted HCV patients

MMF does not appear to have a significant antiviral effect despite early reports. Male gender of donors and recipients, living donors, cold ischemia times, acute rejection, and early histological recurrence are related to the development of advanced hepatitis.
1. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. 

2. Transplantation 2008; 86: 1689-1694 [PMID: 19104406 DOI: 10.1097/TP.0b013e318188f6e4]

3. Boillot O, Mayer DA, Boudjema K, Salizzoni M, Griddelli B, Filippini F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit M, Mangeret R, Pallardo JM, Hoekstra K, Pageaux GP. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transplant 2005; 11: 61-67 [PMID: 15690537 DOI: 10.1002/lt.20307]

4. Bonaccorsi-Riani E, Sempoux C, Piette N, Julliard O, Kabamba B, Ciccarelli O, Roggen F, De Reyck C, Hassoun Z, Lerut Z. Impact of steroid-avoidance immunosuppression on long-term outcome after liver transplantation for HCV cirrhosis: the need for well documented long-term follow-up. Acta Gastroenterol Belg 2012; 75: 411-418 [PMID: 23402884]

5. Cholongitas E, Shusang V, Germani G, Tschantzis E, Raimondo ML, Marelli L, Zenzlo M, Davidson BR, Patch D, Rolles K, Burroughs AK. Long-term follow-up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin. Clin Transplant 2011; 25: 614-624 [PMID: 20718824]

6. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396-1399 [PMID: 12717237 DOI: 10.1097/01.TP.0000062834.30922.FE]

7. Filippini F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, Risaliti A, Burra P, Agnes S, De Carlis L, Valente U, Ferrara R, Pisati R. Double-blind comparison of heparin C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2005; 79: 1488-1495 [PMID: 15990133]

8. Gerhardt T, Terjung B, Knipper P, Palmedo H, Woitas RP, Kalf K, Sauerbruch T, Spengler U. Renal impairment after liver transplantation - a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation. Eur J Med Res 2009; 14: 210-215 [PMID: 19541578]

9. Junge G, Neuhaus R, Schewior L, Klupp J, Guckelberger O, Langrehr JM, Tullius S, Neuhaus P. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc 2005; 37: 1695-1696 [PMID: 15991434]

10. Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, Nishida S, Moon J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplantation recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007; 84: 829-835 [PMID: 17984834 DOI: 10.1097/01.tp.0000282914.20578.7b]

11. Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Eckhoff DE, Netto GJ, Katz E. Corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transplant 2007; 13: 1521-1531 [PMID: 17969201 DOI: 10.1002/lt.21162]

12. Lupo L, Ricci P, Caputi L. Basiliximab vs steroids in liver transplantation immunosuppression. A prospective randomized clinical trial [abstract]. Liver Transplant 2005; 11: C75

13. Langrehr JM, Neumann UP, Lang M, Müller AR, Jonas S, Settmacher U, Steimmler T, Neuhaus P. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc 2002; 34: 1567-1566 [PMID: 12176487]

14. Lerut J, Mathys J, Verbaanert C, Talpe S, Ciccarelli O, Lemaire J, Bonaccorsi-Riani E, Vanhuyse V, Hetsch N, Roggen F, Reyck CD, Goffette P, Latinne D, Orlando G, Rahier J, Sempoux C, Wallemacq P, Laterre PF, Gianello P. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. Ann Surg 2009; 248: 956-967 [PMID: 19092340 DOI: 10.1097/SLA.0b013e3181900959]

15. Lupo L, Panzera P, Tandoi F, Carbotta G, Giannelli G, Santantonio T, Rendina M, Gentile A, Memeo V. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: one year results of a prospective, randomized controlled study. J Hepatol 2006; 44: 710-716 [PMID: 16487622]

16. Nashan B, Lueck R, Becker T, Immunosuprophylaxis without steroids in liver transplanted patients with postnecrotic cirrhosis.
Sgourakis G et al. Corticosteroid-free immunosuppression in LT

rhosis [abstract]. Transpl Int 2001; 14: 338A

28 Neumann U, Samuel D, Truneka P, Gugenheim J, Gerunda GE, Friman S. A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients. J Transplant 2012; 2012: 894215 [PMID: 22690326 DOI: 10.1155/2012/894215]

29 Otero A, Varo E, de Urbina JO, Martín-Vivaldi R, Cuervas-Mons V, González-Pinto I, Rimola A, Bernardos A, Otero S, Maldonado J, Herrero JJ, Barrao E, Domínguez-Granados R. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. Liver Transpl 2009; 15: 1542-1552 [PMID: 19877219 DOI: 10.1002/lt.21854]

30 Pageaux GP, Calmus Y, Boillot O, Ducer C, Vanlemmens C, Boudjema K, Samuel D. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl 2004; 10: 1454-1460 [PMID: 15558584 DOI: 10.1002/lt.20291]

31 Pelletier SJ, Vanderwall K, Debroy MA, Englesbe MJ, Sung RS, Magee JC, Fontana RJ, Punch JD. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transplant Proc 2005; 37: 1214-1216 [PMID: 15848673]

32 Ramirez CB, Doria C, Frank AM, Armenti ST, Marino IR. Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transplant 2013; 27: 463-471 [PMID: 23621629 DOI: 10.1111/ctr.12119]

33 Reggiani P, Arru M, Regazzi M, Gatti S, Molinaro MD, Caccamo L, Maggi U, Melada E, Paone G, Rossi G. A “steroid-free” tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. Transplant Proc 2005; 37: 1697-1699 [PMID: 15919435]

34 Samonakis DN, Mela M, Quaglia A, Triantos CK, Thalheimer U, Leandro G, Pesci A, Raimondo ML, Dhillon AP, Rolles K, Davidson BR, Patch DW, Burroughs AK. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transpl Infect Dis 2006; 8: 3-12 [PMID: 16623815]

35 Studenik P, Mezőlfik V, Stouracova M, Steroid free tacrolimus and mycophenolate mofetil based immunosuppression in liver transplant recipients. Open label, randomised prospective study [abstract]. Liver Transpl 2005; 11: C42

36 Takada Y, Kaido T, Asonuma K, Sakuari H, Kubo S, Kiuchi T, Inomata Y, Isaji S, Tsumura H, Teramukai S, Matsubara Y, Sakabayashi S, Uemoto S. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation. Liver Transpl 2013; 19: 896-906 [PMID: 23696054 DOI: 10.1002/lt.23679]

37 Tisone G, Angelico M, Palmieri G, Pisani F, Anselmo A, Baiocchi L, Negrini S, Orlando G, Vennarecci G, Casciani CU. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999; 67: 1308-1313 [PMID: 10360582]

38 Varo E, Otero A, Ortiz de Urbina J. Steroid-free regimen versus standard treatment in liver transplant recipients [abstract]. Transpl Int 2005; 18: 116

39 Washburn K, Speeg KV, Estel R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001; 72: 1675-1679 [PMID: 11726831]

40 Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blind trial. Transplantation 2010; 90: 1562-1566 [PMID: 21048536 DOI: 10.1097/TP.0b013e3181ff8794]

41 Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath P, Montgomery RA, Cameron AM, Maley WR. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512-525 [PMID: 18383081 DOI: 10.1002/lt.21396]

42 Sgourakis G, Radtke A, Fouzias I, Mylona S, Goumas K, Gockel I, Lang H, Karaliotas C. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009; 22: 892-905 [PMID: 19453997]

43 March J. Levels of evidence (2009). Oxford Centre for Evidence-based Medicine. Available from: URL: http://www.cebmnet/indexaspx?o=1025

P- Reviewer: Bramhall S, Chiu KW, Christofi C, Gangl A, Li JD, Morioka D, Ozden I S- Editor: Gou SX L- Editor: Webster JR E- Editor: Zhang DN
